GSK-TPL108390



Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin)
eltrombopag
TPL108390
NCT00529568
Hepatitis C, Chronic
Phase 3
 
January 2014